Nondystrophic myotonia: Challenges and future directions
- 1 March 2014
- journal article
- editorial
- Published by Elsevier in Experimental Neurology
- Vol. 253, 28-30
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypesExperimental Neurology, 2013
- Measuring quality of life impairment in skeletal muscle channelopathiesEuropean Journal of Neurology, 2012
- Mexiletine for Symptoms and Signs of Myotonia in Nondystrophic MyotoniaJAMA, 2012
- Role of disease severity, illness perceptions, and mood on quality of life in muscle diseaseMuscle & Nerve, 2012
- Ranolazine selectively blocks persistent current evoked by epilepsy‐associated NaV1.1 mutationsBritish Journal of Pharmacology, 2010
- The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatmentBrain, 2009
- Use-dependent block of cardiac late Na+ current by ranolazineHeart Rhythm, 2009
- Redefining the clinical phenotypes of non-dystrophic myotonic syndromesJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Block of Tetrodotoxin-sensitive, Nav1.7, and Tetrodotoxin-resistant, Nav1.8, Na+channels by RanolazineChannels, 2008
- State- and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by RanolazineMolecular Pharmacology, 2008